



Announcement Summary

Entity name
ARGENICA THERAPEUTICS LIMITED

Announcement Type
New announcement

Date of this announcement
Wednesday July 09, 2025

The +securities to be quoted are:
Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

Quotation for securities outlined in Appendix 3G on 3 June 2025. On advice from the ASX, these shares which are subject to voluntary escrow should be quoted as opposed to being put on a restricted unquoted class of securities.

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
AGN	ORDINARY FULLY PAID	352,345	03/06/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

ARGENICA THERAPEUTICS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ACN

Registration number

637578753

1.3 ASX issuer code

AGN

1.4 The announcement is

New announcement

1.5 Date of this announcement

9/7/2025



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

2.2 The +class of +securities to be quoted is:

Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS?

No

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

Quotation for securities outlined in Appendix 3G on 3 June 2025. On advice from the ASX, these shares which are subject to voluntary escrow should be quoted as opposed to being put on a restricted unquoted class of securities.

2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

Not applicable - the entity has arrangements in place with the holder that ensure the securities cannot be on-sold within 12 months in a manner that would breach section 707(3) or 1012C(6)



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities to be quoted in an existing class

ASX +security code and description

AGN : ORDINARY FULLY PAID

Issue date

3/6/2025

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Issue details

Number of +securities to be quoted

352,345

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Refer to Appendix 3G on 3 June 2025. 1,647,655 options have been cancelled which are equal to the value of the exercise proceeds due using the 15 day VWAP of \$0.789 at the notice of exercise.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.650000

Any other information the entity wishes to provide about the +securities to be quoted

The shares are subject to voluntary escrow until the earlier of 3 June 2026 or a Cleansing Prospectus is issued.

The purpose(s) for which the entity is issuing the securities

Other

Please provide additional details

Exercise of options as outlined on Appendix 3G on 3 June 2025.

Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
AGN : ORDINARY FULLY PAID	128,445,190

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
AGNAI : OPTION EXPIRING 06-JUL-2025 EX \$0.65	125,000
AGNAK : OPTION EXPIRING 09-JUN-2026 EX \$0.65	1,000,000
AGNAL : OPTION EXPIRING 31-MAY-2027 EX \$0.93	500,000



Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

9